维普中文期刊产品整合服务
97篇 您的检索式:作者名="Chiu SH"
    题名 作者 年代 出处 被引量
1High-intensity focused ultrasound ablation:An effective bridging therapy for hepatocellular carcinoma patients显示文摘AIM:To analyze whether high-intensity focused ultrasound(HIFU) ablation is an effective bridging therapy for patients with hepatocellular carcinoma(HCC).METHODS:From January 2007 to December 2010,49 consecutive HCC patients were listed for liver transplantation(UCSF criteria).The median waiting time for transplantation was 9.5 mo.Twenty-nine patients received transarterial chemoembolization(TACE) as a bringing therapy and 16 patients received no treatment before transplantation.Five patients received HIFU ablation as a bridging therapy.Another five patients with the same tumor staging(within the UCSF criteria) who received HIFU ablation but not on the transplant list were included for comparison.Patients were comparable in terms of Child-Pugh and model for end-stage liver disease scores,tumor size and number,and cause of cirrhosis.RESULTS:The HIFU group and TACE group showed no difference in terms of tumor size and tumor number.One patient in the HIFU group and no patient in the TACE group had gross ascites.The median hospital stay was 1 d(range,1-21 d) in the TACE group and two days(range,1-9 d) in the HIFU group(P < 0.000).No HIFU-related complication occurred.In the HIFU group,nine patients(90%) had complete response and one patient(10%) had partial response to the treatment.In the TACE group,only one patient(3%) had response to the treatment while 14 patients(48%) had stable disease and 14 patients(48%) had progressive disease(P = 0.00).Seven patients in the TACE group and no patient in the HIFU group dropped out from the transplant waiting list(P = 0.559).CONCLUSION:HIFU ablation is safe and effective in the treatment of HCC for patients with advanced cirrhosis.It may reduce the drop-out rate of liver transplant candidate.Tan To Cheung Sheung Tat Fan See Ching Chan Kenneth SH Chok Ferdinand SK Chu Caroline R Jenkins Regina CL Lo James YY Fung Albert CY Chan William W Sharr Simon HY Tsang Wing Chiu Dai Ronnie TP Poon Chung Mau Lo 2013World Journal of Gastroenterology2013,19,20:23
2Pancreaticoduodenectomy with vascular reconstruction for adenocarcinoma of the pancreas with borderline resectability显示文摘AIM:To analyze whether pancreaticoduodenectomy with simultaneous resection of tumor-involved vessels is a safe approach with acceptable patient survival.METHODS:Between January 2001 and March 2012,136 patients received pancreaticoduodenectomy for adenocarcinoma at our hospital.Seventy-eight patients diagnosed with pancreatic head carcinoma were included in this study.Among them,46 patients received standard pancreaticoduodenectomy(group 1)and32 patients received pancreaticoduodenectomy with simultaneous resection of the portal vein or the superior mesenteric vein or artery(group 2)followed by reconstruction.The immediate surgical outcomes and survivals were compared between the groups.Fifty-five patients with unresectable adenocarcinoma of the pancreas without liver metastasis who received only bypassoperations(group 3)were selected for additional survival comparison.RESULTS:The median ages of patients were 67 years(range:37-82 years)in group 1,and 63 years(range:35-86 years)in group 2.All group 2 patients had resection of the portal vein or the superior mesenteric vein and three patients had resection of the superior mesenteric artery.The pancreatic fistula formation rate was21.7%(10/46)in group 1 and 15.6%(5/32)in group2(P=0.662).Two hospital deaths(4.3%)occurred in group 1 and one hospital death(3.1%)occurred in group 2(P=0.641).The one-year,three-year and five-year overall survival rates in group 1 were 71.1%,23.6%and 13.5%,respectively.The corresponding rates in group 2 were 70.6%,33.3%and 22.2%(P=0.815).The one-year survival rate in group 3 was13.8%.Pancreaticoduodenectomy with simultaneous vascular resection was safe for pancreatic head adenocarcinoma.CONCLUSION:The short-term and survival outcomes with simultaneous resection were not compromised when compared with that of standard pancreaticoduodenectomy.Tan To Cheung Ronnie TP Poon Kenneth SH Chok Albert CY Chan Simon HY Tsang Wing Chiu Dai See Ching Chan Sheung Tat Fan Chung Mau Lo 2014World Journal of Gastroenterology2014,20,46:8
3Survival analysis of breast cancer liver metastasis treated by hepatectomy: A propensity score analysis for Chinese women in Hong Kong显示文摘Background: Survival of patients with breast cancer liver metastasis is very poor. This study aimed to analyze the survival outcome of hepatectomy for this patient population. Methods: From January 1995 to December 2014, 2522 patients with liver cancer received hepatectomy at our hospital. Twenty-one of them, all female, received the operation for breast cancer liver metastasis. Performance was compared with patients with colorectal liver metastasis treated with hepatectomy after propensity score analysis in a ratio of 1:3. Results: Twenty-one patients received hepatectomy for breast cancer. After propensity score matching, 63 patients who had hepatectomy for colorectal cancer were selected for comparison. There was no significant difference in immediate or short-term outcomes between the two groups of patients in terms of operative time, blood loss and surgical morbidities. All patients with breast cancer had R0 resection. No hospital death occurred. After hepatectomy, the 1-, 3- and 5-year overall survival rates were 100.0%, 58.9% and 58.9% respectively in patients with breast cancer. The 1-, 3- and 5-year overall survival rates were 95.0%, 57.2% and 39.7% respectively in patients with colorectal cancer (P = 0.572). On multivariate analysis, triple negative status was the only independent poor prognostic factor in breast cancer liver metastasis (OR = 6.411;95% CI: 1.351–30.435;P = 0.019). Conclusions: Hepatectomy is a safe and effective way of treating breast cancer liver metastasis at experienced centers where multidisciplinary adjuvant treatments are available. It can be considered more frequently as part of the multidisciplinary care for this patient population.Tan To Cheung Kenneth SH Chok Albert CY Chan Simon HY Tsang Wing Chiu Dai Thomas CC Yau Ava Kwong Chung Mau Lo 2019Hepatobiliary & Pancreatic Diseases International2019,18,5:3
4The impact of family history of hepatocellular carcinoma on its patients' survival显示文摘BACKGROUND:Family history of hepatocellular carcinoma(HCC) has been identified as a risk factor for the development of the disease.The aim of this study is to evaluate the impact of such a history on HCC patients' survival.METHODS:Data of all HCC patients(n=4532) managed at our center from 1989 to 2008 were prospectively collected.The patients were quizzed on their various characteristics including family HCC history.RESULTS:Totally 475(10.48%) patients had a family history of HCC.They presented the disease at a significantly earlier age(median 53 vs 59 years,P<0.0001) and at an earlier stage(the United Network for Organ Sharing staging system).They had significantly better liver function in terms of ChildPugh classification and serum albumin and bilirubin levels.Significantly more of them presented the disease without symptoms(44.0% vs 29.4%,P<0.0001).They also had significantly better overall survival under these specifications:patients in the whole study cohort,patients who had minor hepatectomy,patients with stage I disease,patients with stage II disease,and patients with stage III disease.CONCLUSIONS:Contrary to what is generally believed,we found in this study cohort that patients with a family history of HCC had better overall survival than those without such a history.We believe this was in part due to earlier diagnosis of the disease and better liver function in this group of patients.However,the effects of genetic factors on the risk of HCC cannot be overlooked and are yet to be identified.Wing Chiu Dai Sheung Tat Fan Tan To Cheung Kenneth SH Chok Albert CY Chan Simon HY Tsang Ronnie TP Poon Chung Mau Lo 2012Hepatobiliary & Pancreatic Diseases International2012,11,2:2
5Hepatopancreatoduodenectomy for advanced hepatobiliary malignancies: a single-center experience显示文摘BACKGROUND:Hepatopancreatoduodenectomy is a complicated and challenging procedure but necessary for curative resection for advanced hepatobiliary malignancies.This retrospective study was to examine the safety and survival outcomes of hepatopancreatoduodenectomy in our center.METHODS:Prospectively collected data of 12 patients who underwent hepatopancreatoduodenectomy for advanced hepatobiliary malignancies in our hospital from January 1998 to December 2014 were analyzed.The primary endpoints are treatment-related morbidity and mortality and the secondary endpoints are overall survival and disease-free survival.RESULTS:Curative resection was achieved in 11(91.7%) patients.Complications developed in 10(83.3%) patients.Three hospital deaths resulted from multiorgan failure secondary to postoperative pancreatic fistula or hepaticojejunostomy leakage.Six of the nine remaining patients had disease recurrence.The nine patients had a median survival of 39.8(5.3-151.8) months.The 1-,3- and 5-year overall survival rates were 66.7%,55.6% and 27.8%,respectively.The corresponding disease-free survival rates were 55.6%,44.4% and 29.6%,respectively.CONCLUSIONS:Morbidity and mortality after hepatopancreatoduodenectomy were significant.With R0 resection,the 5-year overall survival and disease-free survival rates were 27.8% and 29.6%,respectively.Wing Chiu Dai Kenneth SH Chok Tan To Cheung Albert CY Chan See Ching Chan Chung Mau Lo 2017Hepatobiliary & Pancreatic Diseases International2017,16,4:2
6Interleukin-6 induced basic fibroblast growth factor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and PI3-kinase/Akt path ways显示文摘Jee SH Chu CY Chiu H 2004J Invest Dermatol2004,123,6:1
7Over-expression of interleukin-6 in human basel cell lines increases anti-apoptotic activity and tumoergenic potency 显示文摘Jee SH Shen SC Chiu HC 2001Oncogene2001,20,2:1
8Correlation between Glasgow co- ma score components and survival in patients with traumatic brain in- jury 显示文摘Kung WM Tsai SH Chiu WT 2011Injury2011,42,9:1
9Epidemiologic trends in nos- ocomial bacteremia in a neonatal intensive care unit 显示文摘Wei SH Chiu HH Hung KC 2005J /Vti- crobiol Immunol Infect2005,38,4:1
10Multiple defects in antigenpresentation and T cell development by mice expressing cytoplasmictail-truncated CDld显示文摘Chiu YH Park SH Benlagha K 2002Nat Immunol2002,,:1
11Interleukin-6 induced basic fibroblast growth aetor-dependent angiogenesis in basal cell carcinoma eell line via JAK/STAT3 and PI3-ki-nase/Akt pathways 显示文摘Jee SH Chu CY Chiu HC el al 2004J Invest Dermatol2004,123,6:1
12Separation of thoracopagus conjoined twins:A case report显示文摘Chiu CT Hou SH Lai HS 1994J Cardiovasc Surg1994,35,5:1
13The impact of time, legislation, and geography on the epidemiology of traumatic brain injury 显示文摘Chiu WT Huang SJ Tsai SH 2007J Clin Neurosci2007,14,10:1
14Interleukin-6 induced basic fibroblast growth actor-dependent angiogenesis in basal cell carcinoma cell line via JAK/STAT3 and Pl3-ki- nase/Akt pathways 显示文摘Jee SH Chu CY Chiu HC 2004J Invest Dermatol2004,123,6:1
15Childhood obesity and dental caries in homeless children 显示文摘Chiu SH Dimarco MA Pmkop JL 2013J Pediatr Health Care2013,27,4:1
16Association of peripheral total and differential leukocyte counts with metabolic syndrome and risk of isehemie cardiovascular diseases in patients with type 2 diabetes mellitus显示文摘Tsai JC Sheu SH Chiu HC 2007Diabetes Metah Res Rev2007,23,2:1
17Epidemiologic trends in nosoeo- mial bacteremia in a neonatal intensive care unit显示文摘Wei SH Chiu HH Hung KC 2005Microbiol Immu- nol Infect2005,38,4:1
18The dynamic flammability and toxicity of magnesium hydroxide filled intumescent fire retardant polypropylene显示文摘Chiu SH Wang WK 1998Appl Polym Sci1998,,67:1
19The impact of exsanguina- tion by Esmarch bandage on venous hemodynamic changes in total knee arthroplasty - A prospective randomized study of 38 knees 显示文摘Chiu FY Hung SH Chuang TY 2012Knee2012,19,3:1
20Separation of thoracopagus conjoined twins,a case report显示文摘Chiu CT Hou SH Lai HS 1994J Cardiovasc Surg1994,35,5:1
返回顶部 每页显示:
共5页 首页 上一页 第1页 下一页 末页 /5 跳转

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1 渝公网安备 50019002500403号 违法和不良信息举报中心

互联网出版许可证 新出网证(渝)字10号 全国400电话 - 免长途话费